NCT07211815 is a clinical trial in Primary Liver Cancers, sponsored by Chifeng Tumor Hospital.

Who is sponsoring NCT07211815?

NCT07211815 is sponsored by Chifeng Tumor Hospital.

What condition does NCT07211815 study?

NCT07211815 studies Primary Liver Cancers.

Is NCT07211815 still recruiting?

NCT07211815 is currently not yet recruiting. Last updated 8 October 2025.

Last reviewed 2025-10-08 · How we verify

NCT07211815

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dosimetric Differences and Clinical Significance Analysis Between Body Gamma Knife and VMAT Radiotherapy for Primary Liver Cance

Not yet recruiting Last updated 8 October 2025

What this trial tests

trial in Primary Liver Cancers in 30 participants. Not yet recruiting.

Timeline

1 November 2025

Primary endpoint
1 June 2027

1 June 2027

Quick facts

Lead sponsor	Chifeng Tumor Hospital
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 November 2025
Primary completion	1 June 2027
Estimated completion	1 June 2027
Sites	1 location across China

Conditions studied

Primary Liver Cancers — all drugs for Primary Liver Cancers →

Sponsor

Chifeng Tumor Hospital

Who can join

Adults 18 to 75, any sex, with Primary Liver Cancers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To fill in the "Brief Summary" field, you need to provide clear, easy-to-understand information about the study for patients, families, and healthcare providers. Here's a suggested summary: This study compares the dosimetric features and clinical effects of body gamma knife and VMAT radiotherapy for locally advanced primary liver cancer. We retrospectively analyze 20 patients from Chifeng Tumor Hospital who cannot or refuse surgery. For each patient, we will develop both body gamma knife and VMAT radiotherapy plans. Then, we'll compare the dose distribution in the tumor target (including conformity index and homogeneity index) and the radiation exposure to organs at risk (such as the spinal cord, stomach, and liver). The goal is to find out which radiotherapy approach is more beneficial, so patients, families, and healthcare teams can better understand how this research supports treatment decisions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Chifeng Tumor Hospital trials

Trials by the same sponsor.

NCT07242911 — Study on Efficacy and Safety of VMAT Technique With Local Dose Escalation for Unresectable Pancreatic Cancer · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07211815 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chifeng Tumor Hospital
Last refreshed: 8 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07211815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing